Negotiations To Control Spanish Health Spending

23 January 1995

In an attempt to control national spending on health care, the Spanish government is looking to reach an agreement with the national pharmaceutical industry association, Farmaindustria, which may result in a 20% reduction in supplies and controls on expenditure.

Negotiations are underway to control pharmaceutical spending through to 1997. The Ministry of Health and Farmaindustria are finalizing an agreement which will include, among other things, a plan to contain pharmaceutical expenditure, reports the Spanish financial daily, Cinco Dias. The Ministry wants to establish in writing how much pharmaceutical spending will increase between 1995 and 1997. The industry association has indicated that it considers this to be a good move, enabling drug companies to plan their production levels.

The Ministry is, at the same time, in negotiations with suppliers to reach an agreement to reduce the price of supplies. It is understood that in 1995 the budget will allow for a reduction in the time to pay to 90 days and discounts of 20%. At the moment, private health care companies pay up to 20% less for hospital supplies than state-funded care.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight